RecruitingPhase 1NCT07450911
A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System
Sponsor
ReValve Solutions Inc.
Enrollment
20 participants
Start Date
Sep 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
An evaluation of the ReValve System for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a medical device called ReValve System for people with mitral regurgitation. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEReValve System
Mitral Valve Replacement Device
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07450911
Related Trials
Capstan Medical TMVR Study: FIH
NCT066001913 locations
Cephea Early Feasibility Study
NCT0506100422 locations
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
NCT0549699837 locations
The CardioClip Study
NCT062414301 location
Abbott Cephea Mitral Valve Disease Registry
NCT0706967323 locations